top of page

A SHORT GUIDE TO 
Achieving Market Access for a Rare Disease Therapy
in Asia Pacific

Request our short guide .pdf

We will send you our short guide to Achieving Market Access for a Rare Disease Therapy in Asia Pacific.

​

  • What are the sources of funding for rare disease therapies?

  • What are the pockets of funding you may not have heard of?

  • How do the funding pathways differ versus non-rare disease?

  • What are the decision criteria?

  • What barriers to access should you be preparing for?

Request the EMAX short guide

EMAX-Solutions---Short-Guide-To-Achievin

Thanks! Your guide will soon be on its way. Please check your email.

Terms

Registering your interest for this guide will NOT result in your email address being automatically placed on a distribution list.

Understand the funding landscape for rare disease therapies across 12 markets in Asia Pacific

OUR APPROACH

WHAT'S DIFFERENT ABOUT EMAX SOLUTIONS?

EMAX-Solutions---Short-Guide-To-Achievin

Request our short guide .pdf
A short guide to Achieving Market Access for a Rare Disease Therapy in Asia Pacific

WE SPECIALISE IN ASIA AND EMERGING MARKETS

Between our in-house consultants and network of market specialists and on-the-ground experts, everyone that works on your project team will bring local market expertise and experience of the access environment. This ensures we can direct you to the optimal access pathway for your product, which in Asia Pacific and emerging markets, is not always obvious. It also ensures we know what you need to do to successfully navigate that pathway in the shortest possible time.
 

WE PROVIDE BOTH INNOVATIVE APPROACHES AND EFFECTIVE IMPLEMENTATION 

Achieving your desired business impact for a drug or device in Asia Pacific, Latin America and other emerging markets requires an innovative approach to market access, as well as effective implementation. We can help with both, devising the right access and commercial strategy and supporting local teams in their execution, ensuring that your access-related goals are met.

​

WE DELIVER ACCESS INSIGHTS THAT ARE CREDIBLE, MEANINGFUL AND ACTIONABLE

This requires speaking with the right stakeholders, which is why we personally manage a network of stakeholders from across the pharma and device value-chains in more than 25 markets in Asia Pacific and emerging markets. Our understanding of the markets also ensures we ask the right questions and, by conducting all stakeholder discussions ourselves, we ensure every one you commission us to do is a high-grade interaction that generates the insights you need. This is how we ensure our insights will help you make better informed access decisions in Asia Pacific and emerging markets.

​

WE CAN HELP YOU MAXIMISE PRIVATE, AS WELL AS REIMBURSEMENT, OPPORTUNITIES 

We can do more than just help you navigate the shifting requirements of the HTA environments of Asia Pacific and emerging markets.  We can help you develop and execute the right strategy for achieving commercial success in the private sector too. This may be  through traditional private health insurance, innovative "wellness plans", corporate clinic providers or, of course, patient self-pay programmes.

Selecting the right patient-pay model, and executing it effectively, depends on the brand, your reimbursement objectives and timelines and local market conditions. The traditional "Buy Some, Get Some Free" model, may not be the best option. Whether its payment-by-instalment, provider collaborations or some other approach, we have the experience to design the right programme and guide you to effective implementation.

WHY CHOOSE EMAX?

Identify the pockets of funding available for your product and how to access them

SingaporeWash.jpg

HOW WE WORK

METHOD TO OUR SUCCESS

The first question we help our clients answer:

What are the barriers preventing eligible patients receiving our treatment or product?

​

To answer this question we take a broad perspective to access and explore what barriers may reside not just on the pricing & reimbursement decision-making pathway, but also along provider and institutional funding flows, patient journeys, HCP referral pathways and product distribution flows.

​

The second, broad, question we help our clients answer:

How to do we best navigate past these barriers to accelerate funding timelines and ensure optimal patient access and coverage for our product?

​

Answering this question may involve investigating the likely reception for a new technology from P&R authorities, exploring partnership opportunities with a provider, developing stakeholder engagement strategies or designing and implementing a self-pay access programme.

​

If you’d like to discuss how we may be able to help you identify and navigate past a particular challenge you have, contact us at info@emax-solutions.com or click here

HOW WE WORK

Make better-informed pricing and access decisions in Asia Pacific and emerging markets

CASE STUDIES
TESTIMONIALS
Aerial.jpg

TESTIMONIALS

EMAX Solutions is a flexible and easy-to-work-with provider that is able to leverage expertise in developed markets to uncover meaningful insights in emerging markets. EMAX Solutions' work is high quality and has been widely used in my organisation and is a continuous input in to other projects.

Johannes Gambari

Pricing & Access, Takeda Emerging Markets

We engaged EMAX Solutions to work on a complex aspect of pricing policy in Asia. This is not an easy area, since most of the times the processes are not formal and transparent. EMAX Solutions was able to navigate through the complexities to come up with good insights and recommendations that will help us make better informed decisions

APAC Pricing & HTA Lead

Swiss pharma manufacturer

CLIENTS

CLIENTS WE HAVE WORKED WITH

bottom of page